{"protocolSection": {"identificationModule": {"nctId": "NCT01070043", "orgStudyIdInfo": {"id": "CVAA489ATW01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone", "officialTitle": "A Single Center, Randomized, Double-blind, Active Controlled, Parallel Group Study to Demonstrate Non-inferiority of a Fixed Dose Combination of 5 mg Amlodipine and 80 mg Valsartan to 160 mg Valsartan in the Treatment of Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-06", "studyFirstSubmitQcDate": "2010-02-16", "studyFirstPostDateStruct": {"date": "2010-02-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-09-13", "resultsFirstSubmitQcDate": "2011-09-13", "resultsFirstPostDateStruct": {"date": "2011-10-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-09-13", "lastUpdatePostDateStruct": {"date": "2011-10-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study was to assess efficacy and safety of fixed dose combination of 5 mg amlodipine/80 mg valsartan compared to 160 mg valsartan monotherapy in lowering blood pressure in Taiwanese patients."}, "conditionsModule": {"conditions": ["Hypertension", "High Blood Pressure"], "keywords": ["Hypertension", "valsartan", "amlodipine", "high blood pressure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 60, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Amlodipine 5mg/Valsartan 80 mg", "type": "EXPERIMENTAL", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.", "interventionNames": ["Drug: Amlodipine 5mg/Valsartan 80 mg"]}, {"label": "Valsartan 160 mg", "type": "ACTIVE_COMPARATOR", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.", "interventionNames": ["Drug: Valsartan"]}, {"label": "Run-In Valsartan 80 mg", "type": "OTHER", "description": "During run-in period, oral valsartan 80 mg once daily for 4 weeks.", "interventionNames": ["Drug: Valsartan"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine 5mg/Valsartan 80 mg", "description": "Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.", "armGroupLabels": ["Amlodipine 5mg/Valsartan 80 mg"], "otherNames": ["Exforge"]}, {"type": "DRUG", "name": "Valsartan", "description": "For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.\n\nMonotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks", "armGroupLabels": ["Run-In Valsartan 80 mg", "Valsartan 160 mg"], "otherNames": ["Diovan"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement", "description": "Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting systolic blood pressure (msSBP) was calculated comparing the Week 8 readings to the readings taken at baseline.", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement", "description": "Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting diastolic blood pressure (msDBP) was calculated comparing the Week 8 readings to the readings taken at Baseline.", "timeFrame": "Baseline and 8 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours", "description": "Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean systolic blood pressure (mSBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind phase.", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Change From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase", "description": "Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean diastolic blood pressure (mDBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind.", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Number of Participants With Adverse Events During Double-blind Phase", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants over 18 years of age with hypertension defined as sitting systolic blood pressure between 140 mmHg and 180 mmHg or sitting diastolic blood pressure between 90 mmHg and 120 mmHg.\n* High risk participants ( defined as having: (diabetes mellitus, chronic renal disease, Framingham 10-year risk score \\>10%, established coronary artery disease (CAD), or CAD equivalents including carotid artery disease, peripheral arterial disease (PAD), abdominal aortic aneurysm (AAA))with hypertension defined as sitting systolic blood pressure between 130 mmHg and 180 mmHg or sitting diastolic blood pressure between 80 mmHg and 120 mmHg.\n\nExclusion Criteria:\n\n* Known or suspected secondary hypertension\n* Known New York Heart Association (NYHA) functional class IV Heart Failure\n* History of myocardial infarction, transient ischemic attack or cerebrovascular accident within the preceding 3 months\n* Clinically significant valvular disease\n* Women who are pregnant, intend to become pregnant or are breastfeeding\n* Participants who have severe medical condition(s) that in the view of the Investigator prohibits participation in the study\n* Participants who have hypersensitivity to the investigational/ reference drug or any of the components in the formulation.\n* Other protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Novartis", "affiliation": "Novartis", "role": "STUDY_CHAIR"}], "locations": [{"city": "Taipei", "zip": "11217", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A 4 week run-in phase preceded the randomized, double-blind treatment phase of the study. During the run-in phase, participants took valsartan 80 mg daily before a meal. Sixty participants entered the run-in phase. Those participants who met the inclusion criteria entered the randomized, double-blind treatment phase.", "groups": [{"id": "FG000", "title": "Run-In Valsartan 80 mg", "description": "During run-in period, oral valsartan 80 mg once daily for 4 weeks."}, {"id": "FG001", "title": "Amlodipine 5 mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks."}, {"id": "FG002", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks."}], "periods": [{"title": "Run-In Phase", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "60"}, {"groupId": "FG001", "comment": "This combination therapy arm is used only for double-blind phase.", "numSubjects": "0"}, {"groupId": "FG002", "comment": "This monotherapy (Valsartan 160 mg) treatment arm is used only for double-blind phase.", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Did not Meet Inclusion Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Double-Blind Treatment", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "21"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Amlodipine 5mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks."}, {"id": "BG001", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "42"}]}], "measures": [{"title": "Age Continuous", "description": "Baseline measurements were based on safety/intent-to-treat (ITT) population.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.50", "spread": "13.81"}, {"groupId": "BG001", "value": "55.13", "spread": "11.81"}, {"groupId": "BG002", "value": "57.31", "spread": "13.81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "17"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "25"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement", "description": "Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting systolic blood pressure (msSBP) was calculated comparing the Week 8 readings to the readings taken at baseline.", "populationDescription": "The Intent-to-Treat (ITT) Population includes all participants having taken at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "150.26", "spread": "12.91"}, {"groupId": "OG001", "value": "141.14", "spread": "12.71"}]}]}, {"title": "8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "133.79", "spread": "14.63"}, {"groupId": "OG001", "value": "133.68", "spread": "12.73"}]}]}, {"title": "Change from baseline to 8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.48", "spread": "15.53"}, {"groupId": "OG001", "value": "-7.23", "spread": "11.60"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement", "description": "Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting diastolic blood pressure (msDBP) was calculated comparing the Week 8 readings to the readings taken at Baseline.", "populationDescription": "The Intent-to-Treat (ITT) Population includes all participants having taken at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.12", "spread": "10.84"}, {"groupId": "OG001", "value": "89.98", "spread": "9.37"}]}]}, {"title": "8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.29", "spread": "8.74"}, {"groupId": "OG001", "value": "86.73", "spread": "9.10"}]}]}, {"title": "Change from baseline to 8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.83", "spread": "7.66"}, {"groupId": "OG001", "value": "-2.65", "spread": "6.75"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours", "description": "Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean systolic blood pressure (mSBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind phase.", "populationDescription": "The Intent-to-Treat (ITT) Population includes all participants having taken at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "144.38", "spread": "17.39"}, {"groupId": "OG001", "value": "139.76", "spread": "13.46"}]}]}, {"title": "8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "129.67", "spread": "14.03"}, {"groupId": "OG001", "value": "131.11", "spread": "12.39"}]}]}, {"title": "Change from baseline to 8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.71", "spread": "11.64"}, {"groupId": "OG001", "value": "-6.39", "spread": "12.06"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase", "description": "Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean diastolic blood pressure (mDBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind.", "populationDescription": "The Intent-to-Treat (ITT) Population includes all participants having taken at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "86.95", "spread": "14.14"}, {"groupId": "OG001", "value": "87.90", "spread": "9.44"}]}]}, {"title": "8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "79.29", "spread": "10.70"}, {"groupId": "OG001", "value": "82.94", "spread": "8.42"}]}]}, {"title": "Change from baseline to 8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.67", "spread": "7.43"}, {"groupId": "OG001", "value": "-3.56", "spread": "7.70"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events During Double-blind Phase", "populationDescription": "Safety population included all patients who received at least one study medication during the study period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Amlodipine 5 mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks."}, {"id": "OG001", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Total AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "At least one AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "AE Not related to drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "15"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All patients who received at least one study medication during the double-blinded study period were included in the reported safety population.", "eventGroups": [{"id": "EG000", "title": "Amlodipine 5 mg/Valsartan 80 mg", "description": "During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 21, "otherNumAffected": 6, "otherNumAtRisk": 21}, {"id": "EG001", "title": "Valsartan 160 mg", "description": "In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 21, "otherNumAffected": 8, "otherNumAtRisk": 21}], "seriousEvents": [{"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 21}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 - 778- 8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M319", "name": "Amlodipine, Valsartan Drug Combination", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}